(1R,2S,5S)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)Chemicalbookbutanoyl)-6,6-dimethyl-3 CAS 2755812-45-2

Product Description:

ProductName:(1R,2S,5S)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)Chemicalbookbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylicacid CAS 2755812-45-2

Synonyms:

3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-[(2S)-3,3-dimethyl-1-oxo-2-[(2,2,2-trifluoroacetyl)amino]butyl]-6,6-dimethyl-, (1R,2S,5S)-;

Chemical & Physical Properties

Appearance:White powder

Assay: 99%+

Boiling point:495.1±45.0℃

Pka:3.26±0.40

Density:1.290±0.06 g/cm³

Application

It is intermediate of Paxlovid. PF-07321332 (nirmatrelvir) is an oral antiviral clinical lead. It is a covalent inhibitor of SARS-CoV-2 Mpro (main protease, 3CLpro) that binds to cysteine145 within the enzyme's catalytic domain. Mpro is essential for coronavirus replication. Inhibiting Mpro actvity blocks replication at an early stage in the virus' life cycle. Due to structural similarities between the Mpro's of other coronavirusus, PF-07321332 offers the potential of pan-coronavirus activity. In vitro it is suggested to inhibit replication of CoV-2 variants including delta and omicron.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.